You have 9 free searches left this month | for more free features.

carfilzomib

Showing 1 - 25 of 159

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Jun 8, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Multiple Myeloma Trial in Detroit, Charlotte (Carfilzomib, Ruxolitinib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Detroit, Michigan
  • +1 more
Jan 27, 2023

Multiple Myeloma Trial in West Hollywood, Cary (Selinexor, Placebo (for selinexor), carfilzomib)

Withdrawn
  • Multiple Myeloma
  • West Hollywood, California
  • +1 more
Jan 24, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Beverly Hills, California
    Beverly Hills Cancer Center
Dec 21, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
Dec 24, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
Jan 9, 2023

Carfilzomib in Patients With Multiple Myeloma

Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Odense, Denmark
    Odense University Hospital
Dec 20, 2022

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Sep 20, 2023

Kyprolis® in Combination With Revlimid® and Dexamethasone or

Recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
Jun 2, 2022

Anemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Columbus, Salt Lake City (drug, other,

Active, not recruiting
  • Anemia
  • +2 more
  • Carfilzomib
  • +3 more
  • Atlanta, Georgia
  • +2 more
Jan 28, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Multiple Myeloma Trial in United States (daratumumab, carfilzomib, lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Dec 28, 2022

Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,

Active, not recruiting
  • Stage I Multiple Myeloma
  • +2 more
  • Chicago, Illinois
  • +4 more
Sep 3, 2022

Waldenstrom Macroglobulinemia Trial in Hackensack (Carfilzomib, Rituximab, Dexamethasone)

Completed
  • Waldenstrom Macroglobulinemia
  • Carfilzomib
  • +2 more
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Mar 18, 2022

Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)

Active, not recruiting
  • Multiple Myeloma
  • carfilzomib
  • +3 more
  • New York, New York
    Weill Cornell Medical College
Apr 10, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

Recruiting
  • Multiple Myeloma in Relapse
  • Aurora, Colorado
    University of Colorado Hospital
Jan 31, 2023

Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Mar 24, 2022

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Aug 8, 2022